Custirsen
Custirsen, aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival. Custirsen was developed through a collaboration of OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd agreed to develop and commercialise Custirsen.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Custirsen
Custirsen, aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving over all survival. Custirsen was developed through a collaboration of OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd agreed to develop and commercialise Custirsen.
has abstract
Custirsen, aliases including c ...... p and commercialise Custirsen.
@en
CAS number
890056-27-6
chemical formula
C231H312N78O119P20S20
DrugBank
FDA UNII code
L26E95NLRK
Wikipage page ID
60,696,171
page length (characters) of wiki page
Wikipage revision ID
995,241,907
Link from a Wikipage to another Wikipage
CAS number
chemical formula
C231H312N78O119P20S20
@en
ChemSpiderID
34,983,386
drug name
Custirsen
@en
DrugBank
DB05487
@en
synonyms
OGX-011, CC-8490
@en
UNII
L26E95NLRK
@en
wikiPageUsesTemplate
subject
comment
Custirsen, aliases including c ...... p and commercialise Custirsen.
@en
label
Custirsen
@en
sameAs
wasDerivedFrom
isPrimaryTopicOf
name
Custirsen
@en